10-Q: Jazz Pharma Q3 Earnings Beat, Modeyso & Ziihera Drive Growth

Jazz Pharmaceuticals reported a 7% increase in total revenues for Q3 2025, driven by strong performance from Xywav and Epidiolex, alongside new product approvals, despite ongoing litigation costs and competitive pressures.

Summary

• Total revenues increased by 7% to $1.13 billion for the three months ended September 30, 2025, compared to $1.05 billion in the same period of 2024.
• Net income for Q3 2025 was $251.4 million, up from $215.1 million in Q3 2024, with diluted EPS of $4.08.
• For the nine months ended September 30, 2025, the company reported a net loss of $559.6 million, or $(9.18) diluted EPS, primarily due to $947.9 million in acquired in-process research and development (IPR&D) expenses related to the Chimerix acquisition.
• Xywav sales grew 11% to $431.4 million in Q3 2025, driven by increased patient adoption in narcolepsy and idiopathic hypersomnia (IH).
• Epidiolex/Epidyolex sales increased 20% to $302.6 million in Q3 2025, due to higher demand and lower gross-to-net deductions.
• New oncology products Ziihera and Modeyso contributed $8.3 million and $11.0 million in sales, respectively, in Q3 2025.
• Selling, general and administrative (SG&A) expenses surged 63% in Q3 2025 to $530.6 million, largely due to $90.0 million for the Avadel litigation settlement and $61.5 million for Xyrem antitrust litigation settlements.
• A significant income tax benefit of $242.4 million in Q3 2025 resulted from the reversal of a valuation allowance against deferred tax assets acquired through the Chimerix Acquisition, following Modeyso's FDA approval.
• The company made a voluntary repayment of $750.0 million on its Tranche B-2 Dollar Term Loan in January 2025, reducing long-term debt.

Sentiment

Score: 6

Explanation: The company shows strong growth in key products and successful pipeline advancements with new approvals, alongside significant debt reduction. However, a substantial net loss for the nine-month period due to large acquisition-related expenses and litigation settlements, coupled with ongoing competitive pressures and regulatory risks, presents a mixed financial picture. The Q3 performance is positive, but the year-to-date loss and future uncertainties temper overall sentiment.

Positives

• Strong Q3 2025 net income of $251.4 million and diluted EPS of $4.08, an increase from Q3 2024.
• Xywav product sales increased 11% to $431.4 million in Q3 2025, with patient growth of 6% in narcolepsy and 39% in IH.
• Epidiolex/Epidyolex product sales increased 20% to $302.6 million in Q3 2025, driven by increased demand.
• FDA accelerated approval for Modeyso (dordaviprone) in August 2025 for diffuse midline glioma, marking it as the first and only approved treatment for this ultra-rare brain tumor.
• FDA accelerated approval for Ziihera (zanidatamab-hrii) in November 2024 for HER2-positive BTC, with EC conditional marketing authorization in June 2025.
• FDA approval for Zepzelca in combination with atezolizumab in October 2025 for maintenance treatment of extensive-stage SCLC, following positive Phase 3 results.
• Significant income tax benefit of $242.4 million in Q3 2025 due to the reversal of a valuation allowance on deferred tax assets from the Chimerix acquisition.
• Successful global settlement of the Xyrem Antitrust Litigation with a $145.0 million class settlement and confidential settlements with other plaintiffs.
• Global settlement of the Avadel Litigation, including a license agreement for Lumryz with royalties payable to Jazz Pharmaceuticals.
• Voluntary repayment of $750.0 million on the Tranche B-2 Dollar Term Loan in January 2025, contributing to debt reduction.
• New global license agreement with Saniona for SAN2355, expanding the early-stage neuroscience pipeline.

Negatives

• Net loss of $559.6 million for the nine months ended September 30, 2025, compared to net income of $369.0 million in the same period of 2024.
• Diluted EPS of $(9.18) for the nine months ended September 30, 2025, compared to $5.63 in the same period of 2024.
• Acquired in-process research and development (IPR&D) expenses of $947.9 million for the nine months ended September 30, 2025, significantly impacting profitability.
• Xyrem product sales decreased 39% to $35.7 million in Q3 2025 and 41% for the nine months, primarily due to high-sodium oxybate competition and Xywav adoption.
• Royalties and contract revenues decreased 5% in Q3 2025 and 2% for the nine months, mainly due to lower royalty revenue from Hikma's high-sodium oxybate AG.
• Selling, general and administrative (SG&A) expenses increased 63% in Q3 2025 and 38% for the nine months, largely due to litigation settlement expenses totaling $151.5 million in Q3 and $323.5 million for the nine months.
• Defitelio/defibrotide product sales decreased 21% in Q3 2025 and 12% for the nine months due to decreased sales volumes.
• Zepzelca product sales decreased 8% in Q3 2025 and 10% for the nine months due to increased competition in second-line SCLC and treatment protocol updates.
• Rylaze/Enrylaze product sales decreased 5% for the nine months ended September 30, 2025, due to decreased sales volumes and higher gross-to-net deductions, with pediatric asparaginase use remaining below prior levels.
• Ongoing competition from generic and branded oxybate products (e.g., Avadel's Lumryz) continues to impact Xyrem and Xywav sales.
• The FDA litigation regarding Lumryz's approval and Orphan Drug Exclusivity for Xywav was unsuccessful for Jazz Pharmaceuticals.

Risks

• Inability to maintain or increase oxybate revenues due to competition from authorized generic (AG) versions of high-sodium oxybate and branded products like Avadel's Lumryz.
• Increased pricing pressure, changes in policies by, or restrictions on reimbursement imposed by, third-party payors, including the ability to maintain adequate coverage and reimbursement for Xywav.
• Challenges to intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation.
• Inability to maintain or increase sales of Epidiolex/Epidyolex, with expected future competition from generic products.
• Risks associated with effectively commercializing the oncology portfolio (Rylaze, Zepzelca, Ziihera, Modeyso, Defitelio, Vyxeos).
• Failure in clinical development of product candidates, inability to obtain timely regulatory approval, or lower-than-expected sales of approved products.
• Failure to identify, acquire, or in-license additional products or product candidates, or to realize anticipated benefits from such transactions (e.g., Chimerix acquisition).
• Healthcare cost containment and drug pricing scrutiny by regulatory agencies, including the impact of the Inflation Reduction Act of 2022 and potential "Most Favored Nation" pricing policies.
• Global trade issues, tariffs, and export regulations could increase costs, reduce competitiveness, and disrupt the supply chain.
• Disruptions at FDA, SEC, and other government agencies due to funding, workforce reductions, or government shutdowns could delay regulatory processes.
• Changes to tax laws relating to multinational corporations, such as the OECD's Pillar Two initiative and amendments from the IRA, could adversely affect the effective tax rate and liabilities.
• Substantial outstanding debt obligations could impair financial flexibility and access to capital, and the ability to service debt.
• Inability to raise additional capital in a timely manner and on attractive terms, potentially limited by Irish pre-emption rules for equity issuance.
• Dependence on single-source suppliers for most products, product candidates, and APIs, posing supply chain risks.

Future Outlook

The company expects total revenues to increase in 2025 over 2024, driven by growth across its commercial portfolio, offset by a decrease in Xyrem sales due to high-sodium oxybate competition. Selling, general and administrative expenses are expected to increase in 2025 due to litigation settlement expenses, Chimerix integration costs, and commercial portfolio investment. Research and development expenses are projected to decrease in 2025 due to portfolio prioritization, partially offset by Modeyso development costs. The company believes existing cash, cash equivalents, investments, and available credit will be sufficient to fund operations and meet obligations for the foreseeable future, with plans to opportunistically seek additional capital for acquisitions, development, or debt refinancing.

Management Comments

• Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives, advancing robust R&D programs and delivering impactful clinical results, effectively deploying capital to strengthen the prospects of achieving our shortand long-term goals through strategic corporate development, and delivering strong financial performance.
• We view the continued adoption of Xywav in narcolepsy as a positive indication that physicians and patients appreciate the benefits of a low-sodium oxybate option.
• We expect that our business will continue to meaningfully depend on oxybate revenues; however, there is no guarantee that oxybate revenues will remain at current levels.
• We expect total revenues will increase in 2025 over 2024, primarily driven by growth across our commercial portfolio, offset by a decrease in sales of Xyrem due to the impact of high-sodium oxybate competition.
• We believe that our existing cash, cash equivalents and investments balances, cash we expect to generate from operations and funds available under our Amended Revolving Credit Facility will be sufficient to fund our operations and and to meet our existing obligations for the foreseeable future.

Industry Context

Jazz Pharmaceuticals operates in the highly competitive biopharmaceutical industry, focusing on neuroscience and oncology. The company is navigating increasing competition for its key oxybate franchise from generic and branded alternatives, reflecting broader industry trends of patent expirations and market entry by competitors. Regulatory scrutiny on drug pricing, exemplified by the Inflation Reduction Act and 'Most Favored Nation' proposals, poses a significant challenge across the U.S. and international markets. The company's strategy of pipeline expansion through acquisitions (Chimerix) and licensing (Saniona) aligns with industry efforts to diversify revenue streams and address unmet medical needs, particularly in ultra-rare diseases like diffuse midline glioma. The successful resolution of major antitrust and patent litigation reflects the complex legal landscape pharmaceutical companies face in protecting their intellectual property and market position.

Comparison to Industry Standards

• Xywav, with 92% less sodium than high-sodium oxybates, is positioned as a safer alternative, addressing a modifiable risk factor for cardiovascular morbidity, which is a key differentiator in the sleep disorder market compared to competitors like Avadel's Lumryz (same sodium content as Xyrem).
• Modeyso is the first and only FDA-approved treatment for diffuse midline glioma harboring an H3 K27M mutation, positioning Jazz as a leader in this ultra-rare oncology segment, where treatment options are severely limited.
• Ziihera's accelerated approval for HER2-positive BTC and Zepzelca's expanded approval for SCLC maintenance therapy demonstrate the company's ability to bring innovative oncology treatments to market, comparable to other biopharma companies targeting specific cancer types.
• The ongoing patent litigation and generic competition for oxybate products (Xyrem, Xywav) and Epidiolex are standard challenges faced by pharmaceutical companies with successful branded drugs nearing or past patent cliffs, similar to situations seen with other blockbuster drugs.
• The company's substantial debt level and reliance on single-source suppliers are common characteristics in the capital-intensive and complex pharmaceutical manufacturing industry, requiring careful financial and supply chain management.

Corporate Governance

Legal Proceedings

• Xyrem Antitrust Litigation: Resolved with a class settlement agreement of $145.0 million for indirect Xyrem purchasers (final approval October 27, 2025). Confidential settlements also reached with United Healthcare, Federal Opt-Out Plaintiffs, and Aetna. Total expenses of $233.5 million recognized for the nine months ended September 30, 2025.
• Avadel Litigation: Global settlement agreement reached on October 21, 2025, resolving all disputes. Jazz granted Avadel a license for Lumryz with royalties (3.85% for Narcolepsy Indications from Oct 1, 2025; 10% for Non-Narcolepsy Indications from March 1, 2028). Avadel granted Jazz a covenant not to sue for Xywav/Xyrem. Jazz paid Avadel $90.0 million. All matters dismissed with prejudice by October 27, 2025.
• Xywav Patent Litigation: Ongoing patent infringement suits against Lupin, Teva, and Granules India Limited for filing ANDAs for generic versions of Xywav. Lupin received tentative FDA approval in October 2023.
• Zepzelca Patent Litigation: Ongoing patent infringement suits against Zepzelca ANDA Filers for generic versions.
• Defitelio Patent Litigation: Patent infringement lawsuit filed against Almaject for filing an ANDA for a generic version of Defitelio.
• FDA Litigation (Lumryz): Jazz's complaint challenging FDA's approval of Avadel's Lumryz and its Orphan Drug Exclusivity was denied by the District Court in October 2024 and affirmed by the D.C. Circuit in June 2025.
• Qui tam matter: Federal claims dismissed with prejudice and state-law claims dismissed without prejudice by the Court on September 23, 2025.
• Chimerix Acquisition Litigation: Rosenthal Lawsuit dismissed on April 7, 2025, and remaining lawsuits dismissed on June 26, 2025, following supplemental disclosures.

Stakeholder Impact

• Shareholders: Impacted by the net loss for the nine-month period, but also by new product approvals, debt reduction, and ongoing share repurchase program. Litigation settlements represent a significant expense.
• Patients: Benefit from new treatment options like Modeyso (diffuse midline glioma), Ziihera (HER2-positive BTC), and expanded indications for Zepzelca (SCLC). Continued access to Xywav as a low-sodium oxybate option.
• Employees: Impacted by share-based compensation plans and potential for growth in R&D and commercial teams with new product launches.
• Competitors: Face increased competition from Jazz's new product launches and expanded indications, while Jazz faces ongoing generic and branded competition for its key products.
• Regulatory Authorities: Engaged in ongoing patent litigation and regulatory reviews, highlighting the complex relationship between pharmaceutical companies and agencies like the FDA.
• Creditors: Benefit from the company's debt reduction efforts, including the voluntary repayment of $750.0 million on the Tranche B-2 Dollar Term Loan.

Next Steps

• Continue commercialization initiatives for Xywav, Epidiolex/Epidyolex, Rylaze, Zepzelca, Ziihera, and Modeyso.
• Advance robust R&D programs and deliver impactful clinical results, including ongoing Phase 3 trials for zanidatamab and Modeyso.
• Engage with regulatory authorities in Japan regarding a potential JNDA for Epidyolex following Phase 3 trial results.
• Initiate a small Phase 1b trial of JZP441 in narcolepsy Type 1 patients to further understand the compound and orexin-2 receptor agonism.
• Monitor changes in law and guidance in relation to Pillar Two tax rules.
• Opportunistically seek access to additional capital for product acquisition, in-licensing, development, or debt refinancing.
• Continue share repurchases under the New Repurchase Program, with $225.0 million remaining.

Key Dates

Recommendation

Jazz Pharmaceuticals presents a mixed financial picture. While Q3 2025 showed strong revenue growth in key products like Xywav and Epidiolex, and significant new product approvals (Modeyso, Ziihera, Zepzelca expansion) bolster the long-term pipeline, the nine-month period recorded a substantial net loss due to large, non-recurring acquired IPR&D expenses and significant litigation settlements. The company is actively managing its debt and has a robust pipeline. However, ongoing intense competition for its oxybate franchise, persistent drug pricing scrutiny, and the inherent risks of pharmaceutical development and commercialization warrant a cautious approach. The stock may experience volatility as investors weigh the strong Q3 performance and pipeline against the year-to-date losses and future competitive landscape. A 'hold' recommendation allows investors to observe the sustained commercial performance of new launches and the company's ability to mitigate competitive pressures and manage future litigation or regulatory challenges.

Keywords

Jazz Pharmaceuticals, JAZZ, Biopharmaceutical, SEC Filing, 10-Q, Q3 2025, Financial Results, Xywav, Epidiolex, Epidyolex, Modeyso, Ziihera, Zepzelca, Oncology, Neuroscience, Narcolepsy, Idiopathic Hypersomnia, Epilepsy, SCLC, BTC, Diffuse Midline Glioma, Drug Approval, FDA, EC, Litigation Settlement, Antitrust, Patent Infringement, Debt Repayment, Capital Allocation, R&D Pipeline, Pharmaceutical Pricing, Generic Competition, Orphan Drug Exclusivity, Saniona, Chimerix, Avadel, Hikma, Amneal, Share Repurchase, Pillar Two Tax